Screener
BridgeBio Pharma BBIO Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Deferred revenue, current portion | 6,115 | 7,190 |
| 2027 Notes, net | 547,483 | — |
| Other current liabilities (2) | 135,509 | 120,222 |
| Total current liabilities | 816,372 | 287,971 |
| 2033 Notes, net | 619,631 | — |
| 2031 Notes, net | 565,045 | 564,565 |
| 2029 Notes, net | 741,402 | 740,890 |
| 2027 Notes, net | — | 547,015 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's total current liabilities?
- BridgeBio Pharma (BBIO) reported total current liabilities of $816.37M in Q1 2026.
- How has BridgeBio Pharma's total current liabilities changed year-over-year?
- BridgeBio Pharma's total current liabilities increased by 436.7% year-over-year, from $152.11M to $816.37M.
- What is the long-term trend for BridgeBio Pharma's total current liabilities?
- Over 5 years (2020 to 2025), BridgeBio Pharma's total current liabilities has grown at a 24.7% compound annual growth rate (CAGR), from $95.65M to $287.97M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about BridgeBio Pharma's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude